Taylor Ben R 4

What Happened
Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), disposed of a total of 25,334 shares of RXRX in mid‑February 2026. On 2026-02-17, 11,908 shares were withheld by the issuer to satisfy tax obligations from a net settlement of restricted stock units (11,908 @ $3.49 = $41,559). On 2026-02-18, 13,426 shares were sold in an open-market transaction (13,426 @ $3.08 = $41,352). Combined proceeds totaled about $82,911. These were disposals (sales/withholdings), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-17: 11,908 shares withheld for taxes at $3.49 each (F) — $41,559.
  • 2026-02-18: 13,426 shares sold open market at $3.08 each (S) — $41,352.
• Total shares disposed: 25,334; total proceeds ≈ $82,911.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: Shares were withheld by the issuer to satisfy tax withholding on RSU net settlement.
  • F2: The open-market sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Sept 30, 2025.
• Filing: Form 4 filed 2026-02-19 for transactions on 2026-02-17 and 02-18 — appears timely under Form 4 two-business-day reporting rules.

Context
The 02-17 withholding is a common tax-related share retention (net settlement of RSUs) and is recorded as a disposition; it does not necessarily indicate a change in sentiment. The 02-18 sale was executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can reduce the informational value of the sale. Sales by insiders can be routine (taxes, diversification, pre-set plans); they are not inherently a bearish signal.